In this study, different regimens of the study drug are planned to be explored to see which regimen is safe and works the best: • HB-201 alone • A regimen of HB-201 alternating with HB-202 • HB-201 in combination with an FDA-approved drug, Nivolumab • A regimen of HB-201 alternating with HB-202, in combination with an FDA-approved drug Nivolumab
This study is to investigate the study drug in patients with a specific type of cancer called human papillomavirus 16-positive (HPV 16+) cancers. HPV 16+ cancers include head and neck, cervical, anal, vaginal, vulvar, and penile cancers. The main goal of the study is to determine whether HB-201 and HB-202 are effective in the treatment of human papillomavirus 16 positive (HPV 16+) confirmed cancers.
OPEN TO ACCRUAL